Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €64.77 EUR
Change Today +0.72 / 1.13%
Volume 84.9K
MOR On Other Exchanges
Symbol
Exchange
OTC US
OTC US
As of 3:35 PM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

morphosys ag (MOR) Snapshot

Open
€64.19
Previous Close
€64.04
Day High
€65.78
Day Low
€63.96
52 Week High
12/8/14 - €90.00
52 Week Low
03/26/15 - €54.30
Market Cap
1.7B
Average Volume 10 Days
109.1K
EPS TTM
€1.41
Shares Outstanding
26.5M
EX-Date
--
P/E TM
45.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for MORPHOSYS AG (MOR)

Related News

No related news articles were found.

morphosys ag (MOR) Related Businessweek News

No Related Businessweek News Found

morphosys ag (MOR) Details

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies for therapeutic applications. The company, together with its partners, develops a therapeutic pipeline of approximately 80 human antibody drug candidates for the treatment of musculoskeletal diseases, Alzheimer‘s disease, and rheumatoid arthritis. It operates therapeutic development programs for drug candidates in cooperation with various biotechnology and pharmaceutical companies, as well as focuses on the development of proprietary therapeutic antibodies in the area of inflammatory diseases and oncology. The company’s proprietary product candidates include MOR103, an antibody that is in phase Ib trial for multiple sclerosis; MOR202, a therapeutic antibody that is in phase I/II trial for the treatment of multiple myeloma; and MOR208, which is in phase II clinical trials for patients suffering from diffuse large B-cell lymphoma. MorphoSys AG has strategic alliances with Novartis AG for the discovery and development of biopharmaceuticals; and Celgene Corporation for the co-development of the cancer program MOR202. The company was founded in 1992 and is headquartered in Martinsried, Germany.

354 Employees
Last Reported Date: 05/6/15
Founded in 1992

morphosys ag (MOR) Top Compensated Officers

Chairman of Management Board and Chief Execut...
Total Annual Compensation: €751.2K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €509.6K
Chief Development Officer and Member of Manag...
Total Annual Compensation: €504.5K
Chief Scientific Officer and Member of Manage...
Total Annual Compensation: €499.5K
Compensation as of Fiscal Year 2014.

morphosys ag (MOR) Key Developments

MorphoSys Presents Updated Phase 2 Clinical Results for Mor208 Monotherapy in NHL at ASCO Annual Meeting

MorphoSys AG announced updated clinical data on its proprietary drug candidate MOR208. MOR208 is a potent anti-CD19 antibody with a proprietary modification to the Fc portion that is being developed to treat B-cell malignancies. The data, which were presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, are from an ongoing phase 2a study of patients with four different subtypes of relapsed or refractory Non-Hodgkin's Lymphoma (NHL). The clinical data show that MOR208 is well tolerated with a low level of infusion reactions and demonstrates encouraging single-agent activity. Based on these encouraging results, MorphoSys plans to advance MOR208 into two combination trials in DLBCL. The preliminary data presented at ASCO summarize efficacy and safety results for 92 heavily pre-treated patients. The overall response rate was 28% across all four subtypes of NHL and reached 36% in the DLBCL subgroup (both based on evaluable patients). At the time of the analysis, the majority of responders - 16 out of 21 - had an ongoing response to the treatment. The longest response duration observed so far exceeded 14.2 months in DLBCL, 15.4 months in FL and 10.8 months in other iNHL. The open-label, phase 2a, multicenter study was designed to assess the activity and safety of single-agent MOR208 in patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and other indolent NHL (iNHL), who had received at least one prior rituximab-containing therapy. Patients were initially treated with a total of eight weekly doses of 12 mg/kg MOR208. Those with at least stable disease stayed on MOR208 treatment for an additional four weeks. After completion of these twelve weekly doses of treatment, responding patients, who demonstrated at least partial response received maintenance therapy until disease progression or unacceptable toxicity.

Morphosys AG Presents at Deutsche Bank dbAccess German, Swiss & Austrian Conference 2015, Jun-17-2015 05:15 PM

Morphosys AG Presents at Deutsche Bank dbAccess German, Swiss & Austrian Conference 2015, Jun-17-2015 05:15 PM. Venue: Berlin, Germany. Speakers: Claudia Gutjahr-Löser, Head of Corporate Communications & Investor Relations, Jens Holstein, Chief Financial Officer and Member of Management Board.

Morphosys AG Presents at J.P. Morgan Cazenove European Healthcare Conference, Jun-25-2015

Morphosys AG Presents at J.P. Morgan Cazenove European Healthcare Conference, Jun-25-2015 . Venue: London, United Kingdom. Speakers: Claudia Gutjahr-Löser, Head of Corporate Communications & Investor Relations, Jens Holstein, Chief Financial Officer and Member of Management Board.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MOR:GR €64.77 EUR +0.72

MOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €11.05 EUR -0.07
Genmab A/S kr579.50 DKK -2.00
ImmunoGen Inc $14.01 USD -0.26
Intrexon Corp $45.95 USD +0.27
XOMA Corp $3.73 USD -0.025
View Industry Companies
 

Industry Analysis

MOR

Industry Average

Valuation MOR Industry Range
Price/Earnings 47.3x
Price/Sales 14.6x
Price/Book 4.4x
Price/Cash Flow 47.8x
TEV/Sales 12.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MORPHOSYS AG, please visit www.morphosys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.